Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

Open access
Niemann, Carsten U., Herman, Sarah E.M., Maric, Irina, Gomez-Rodriguez, Julio, Biancotto, Angelique, Chang, Betty Y., Martyr, Sabrina, Stetler-Stevenson, Maryalice, Yuan, Constance M., Calvo, Katherine R., Braylan, Raul C., Valdez, Janet, Lee, Yuh Shan, Wong, Deanna H., Jones, Jade, Sun, Clare, Marti, Gerald E., Farooqui, Mohammed Z.H., Wiestner, Adrian·2016·Clinical Cancer Research

Abstract

Purpose: Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B-cell receptor (BCR) signaling. Ibrutinib, a Bruton tyrosine kinase inhibitor, disrupts BCR signaling and leads to the egress of tumor cells from the microenvironment. Although the on-target effects on CLL cells are well defined, the impact on the microenvironment is less well studied. We therefore sought to characterize the in vivo effects of ibrutinib on the tumor microenvironment. Experimental Design: Patients received single-agent ibrutinib on an investigator-initiated phase II trial. Serial blood and tissue samples were collected pretreatment and during treatment. Changes in cytokine levels, cellular subsets, and microenvironmental interactions were assessed. Results: Serum levels of key chemokines and inflammatory cytokines decreased significantly in patients on ibrutinib. Furthermore, ibrutinib treatment decreased circulating tumor cells and overall T-cell numbers. Most notably, a reduced frequency of the Th17 subset of CD4+ T cells was observed concurrent with reduced expression of activation markers and PD-1 on T cells. Consistent with direct inhibition of T cells, ibrutinib inhibited Th17 differentiation of murine CD4+ T cells in vitro. Finally, in the bone marrow microenvironment, we found that ibrutinib disaggregated the interactions of macrophages and CLL cells, inhibited secretion of CXCL13, and decreased the chemoattraction of CLL cells. Conclusions: In conjunction with inhibition of BCR signaling, these changes in the tumor microenvironment likely contribute to the antitumor activity of ibrutinib and may impact the efficacy of immunotherapeutic strategies in patients with CLL. Clin Cancer Res; 22(7); 1572–82. ©2015 AACR. See related commentary by Bachireddy and Wu, p. 1547

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1965

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 201

Metadata

Authors
Niemann, C. U., Herman, S. E. M., Maric, I., Gomez-Rodriguez, J., Biancotto, A., Chang, B. Y., Martyr, S., Stetler-Stevenson, M., Yuan, C. M., Calvo, K. R., Braylan, R. C., Valdez, J., Lee, Y. S., Wong, D. H., Jones, J., Sun, C., Marti, G. E., Farooqui, M. Z. H., & Wiestner, A.
Venue
Clinical Cancer Research
Published
2016-03-31
Volume
22
Issue
7
Pages
1572-1582
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2195033221
Cited by
201
References
5
FWCI
8.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1965
The paper
Niemann, C. U., Herman, S. E. M., Maric, I., Gomez-Rodriguez, J., Biancotto, A., Chang, B. Y., Martyr, S., Stetler-Stevenson, M., Yuan, C. M., Calvo, K. R., Braylan, R. C., Valdez, J., Lee, Y. S., Wong, D. H., Jones, J., Sun, C., Marti, G. E., Farooqui, M. Z. H., & Wiestner, A. (2016). Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1965

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.